Results 31 to 40 of about 125,474 (196)

Short-term tamoxifen administration improves hepatic steatosis and glucose intolerance through JNK/MAPK in mice

open access: yesSignal Transduction and Targeted Therapy, 2023
Nonalcoholic fatty liver disease (NAFLD) which is a leading cause of chronic liver diseases lacks effective treatment. Tamoxifen has been proven to be the first-line chemotherapy for several solid tumors in clinics, however, its therapeutic role in NAFLD
Zhiqiang Fang   +10 more
doaj   +1 more source

Tamoxifen suppresses pancreatic β-cell proliferation in mice.

open access: yesPLoS ONE, 2019
Tamoxifen is a mixed agonist/antagonist estrogen analogue that is frequently used to induce conditional gene deletion in mice using Cre-loxP mediated gene recombination.
Surl-Hee Ahn   +5 more
doaj   +1 more source

Tamoxifen Use in a Patient with Idiopathic Macular Telangiectasia Type 2

open access: yesCase Reports in Ophthalmology, 2018
Crystalline deposits and neurosensory retinal cavitary changes can develop in both tamoxifen retinopathy and nonproliferative idiopathic macular telangiectasia type 2 (MacTel2).
Alice Behrens   +3 more
doaj   +1 more source

Delayed short-term tamoxifen treatment does not promote remyelination or neuron sparing after spinal cord injury.

open access: yesPLoS ONE, 2020
The tamoxifen-dependent Cre/lox system in transgenic mice has become an important research tool across all scientific disciplines for manipulating gene expression in specific cell types.
Nicole Pukos, Dana M McTigue
doaj   +1 more source

The inhibition of tamoxifen on UGT2B gene expression and enzyme activity in rat liver contribute to the estrogen homeostasis dysregulation

open access: yesBMC Pharmacology and Toxicology, 2022
Background Tamoxifen treatment may induce dysregulation of estrogen homeostasis, leading to the occurrence of related adverse reactions. However, the potential mechanisms are still unclear.
Zhixiang Hao   +9 more
doaj   +1 more source

The tamoxifen dilemma [PDF]

open access: yesCarcinogenesis, 1999
The anti-oestrogen tamoxifen is widely used for adjuvant therapy in the treatment of women with breast cancer and has a low incidence of serious side-effects. It could also play a role as a breast cancer chemopreventive agent. However, epidemiological studies in both tamoxifen-treated breast cancer patients and in healthy women have shown that ...
openaire   +2 more sources

Plasma rich-platelet (PRP) potentially attenuates tamoxifen spermatogenic dysfunction in rat's model: sperm quality, histomorphometric, and apoptosis assessment [PDF]

open access: yesAsia Pacific Journal of Medical Toxicology
Background: Tamoxifen induces testicular atrophy and azoospermia. Conversely, platelet-rich plasma (PRP) is a distinctive analog yield enriched with cytokines and growth factors for improving tissue regeneration.
Hossein Hamali   +3 more
doaj   +1 more source

CYP2D6 genotype and tamoxifen response for breast cancer: a systematic review and meta-analysis. [PDF]

open access: yes, 2013
OBJECTIVE: To evaluate evidence on the association between CYP2D6 genotype and tamoxifen response through. DESIGN: Systematic review and meta-analysis of prospective, cross-sectional and case-control studies published to 2012.
Danny W. K. Lum   +18 more
core   +1 more source

The response of anti-VEGF therapy and tamoxifen withdrawal of tamoxifen-induced cystoid macular edema in the same patient

open access: yesBMC Ophthalmology, 2021
Background Numerous cases with ocular toxicity secondary to tamoxifen have been reported, and became more apparent with keratopathy, cataract, optic neuritis, macular holes, crystalline retinopathy with or without cystoid macular edema (CME). Withdrawing
Chuanyu Li   +4 more
doaj   +1 more source

Prevention of Breast cancer with tamoxifen:preliminary findings from the italian randomised trial among hysterectomised women [PDF]

open access: yes, 1998
Prevention of breast cancer with tamoxifen: preliminary findings from the Italian randomised trial among hysterectomised women. Italian Tamoxifen Prevention Study. Veronesi U, Maisonneuve P, Costa A, Sacchini V, Maltoni C, Robertson C, Rotmensz N, Boyle
ROTMENSZ N   +10 more
core   +1 more source

Home - About - Disclaimer - Privacy